

Treatment Naïve and Treatment Experienced

Sofosbuvir and Ribavirin +/- Peginterferon in GT 1-3 ELECTRON Trial (Arms 1-8)


Gane EJ, et al. N Engl J Med. 2013;368:34-44.

Sofosbuvir and Ribavirin +/- Peginterferon in GT 1-3 ELECTRON Trial (Arms 1-8): Features

ELECTRON Trial (Arms 1-8): Features

- **Design:** Randomized, double-blind, phase 2a trial comparing different combinations of sofosbuvir and ribavirin with or without peginterferon
- **Setting:** 2 hepatitis C treatment centers in New Zealand
- **Entry Criteria**
 - HCV RNA > 50,000 IU/mL
 - No cirrhosis
- **Study Arms**
 - Arms 1-6: genotype 2,3 treatment naïve: SOF + RBV +/- PEG
 - Arm 7: GT 1; treatment experienced, prior null responder: SOF + RBV
 - Arm 8: GT 1; treatment naïve: SOF + RBV
- **Primary End-Point:** SVR12

Sofosbuvir and Ribavirin +/- Peginterferon in GT 1-3 ELECTRON Trial (Arms 1-8): Design



Drug Dosing


Sofosbuvir (SOF): 400 mg once daily

Ribavirin (RBV) weight-based and divided bid: 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg

Peginterferon alfa-2a (PEG): 180 µg once weekly

Sofosbuvir and Ribavirin +/- Peginterferon in GT 1-3 ELECTRON Trial (Arms 1-8): Results

ELECTRON: SVR 12, by Treatment Regimen



Source: Gane EJ, et al. N Engl J Med. 2013;368:34-44.

Sofosbuvir + RBV in Treatment-Experienced HCV GT 2 or 3 ELECTRON Trial (Arms 1-8): Conclusions

Conclusions: “Sofosbuvir plus ribavirin for 12 weeks may be effective in previously untreated patients with HCV genotype 1, 2, or 3 infection.”

This slide deck is from the University of Washington's *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online

www.hepatitisc.uw.edu

Hepatitis Web Study

<http://depts.washington.edu/hepstudy/>

Funded by a grant from the Centers for Disease Control and Prevention.